FDA Approves First Oral Drug for Spinal Muscular Atrophy, Evrysdi (Risdiplam)

MONDAY, Aug. 10, 2020 -- The U.S. Food and Drug Administration has approved the first oral, at-home drug for spinal muscular atrophy (SMA), the agency announced Friday.

Evrysdi (risdiplam) was approved to treat patients ages 2 months and older with...